3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025

As the United States market kicks off a holiday-shortened week, major stock indexes like the S&P 500, Nasdaq, and Dow Jones Industrial Average have shown gains, buoyed by advances in tech shares and record highs in gold and silver. Amidst this positive momentum, investors are keenly focused on identifying stocks that may be trading below their intrinsic value, presenting potential opportunities for those looking to capitalize on undervalued assets.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
Zymeworks (ZYME)	$27.23	$52.66	48.3%
UMB Financial (UMBF)	$118.95	$233.99	49.2%
Sportradar Group (SRAD)	$22.86	$45.29	49.5%
SmartStop Self Storage REIT (SMA)	$31.38	$61.01	48.6%
QXO (QXO)	$21.80	$43.29	49.6%
Krystal Biotech (KRYS)	$240.80	$473.18	49.1%
DexCom (DXCM)	$66.06	$127.18	48.1%
Community West Bancshares (CWBC)	$23.00	$44.11	47.9%
Columbia Banking System (COLB)	$28.85	$57.13	49.5%
BioLife Solutions (BLFS)	$25.07	$49.99	49.9%

Click here to see the full list of 209 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Alkami Technology (ALKT)

Overview: Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States and has a market capitalization of approximately $2.39 billion.

Operations: The company generates revenue from its Internet Software & Services segment, amounting to $412.50 million.

Estimated Discount To Fair Value: 26.1%

Alkami Technology is trading at US$22.73, significantly below its estimated fair value of US$30.77, suggesting it may be undervalued based on cash flows. Despite a recent stock price decline and insider selling, the company is poised for high revenue growth of 20.9% annually and is expected to become profitable in three years. Recent strategic initiatives include launching Alkami Foundry to enhance platform development and partnerships, potentially bolstering long-term growth prospects.

• The analysis detailed in our Alkami Technology growth report hints at robust future financial performance.
• Click here and access our complete balance sheet health report to understand the dynamics of Alkami Technology.

Repligen (RGEN)

Overview: Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems across North America, Europe, the Asia Pacific, and internationally, with a market cap of approximately $9.14 billion.

Operations: Repligen's revenue from medical products totals $707.89 million.

Estimated Discount To Fair Value: 11%

Repligen Corporation, trading at US$162.38, is below its fair value estimate of US$182.51, indicating potential undervaluation based on cash flows. The company's earnings are forecast to grow significantly at 45% annually over the next three years, outpacing the broader U.S. market's growth rate. Recent product launches in high-performance chromatography resins aim to bolster its bioprocessing portfolio and drive future revenue growth despite insider selling and modest return on equity projections.

• In light of our recent growth report, it seems possible that Repligen's financial performance will exceed current levels.
• Dive into the specifics of Repligen here with our thorough financial health report.

Tutor Perini (TPC)

Overview: Tutor Perini Corporation is a construction company that offers general contracting, construction management, and design-build services to both private clients and public agencies globally, with a market cap of approximately $3.69 billion.

Operations: The company's revenue segments consist of Specialty Contractors generating $742.35 million, Civil (Including Management Services) contributing $2.86 billion, and Building (Including Management Services) accounting for $1.77 billion.

Estimated Discount To Fair Value: 12.7%

Tutor Perini, priced at US$69.99, trades below its estimated fair value of US$80.19, reflecting undervaluation based on cash flows. Recent earnings show a turnaround with a net income of US$3.63 million for Q3 2025 compared to a loss previously. The company initiated a dividend and announced a US$200 million buyback program, signaling confidence in future growth despite slower revenue expansion forecasts compared to some peers and industry benchmarks.

• According our earnings growth report, there's an indication that Tutor Perini might be ready to expand.
• Delve into the full analysis health report here for a deeper understanding of Tutor Perini.

Make It Happen

• Click here to access our complete index of 209 Undervalued US Stocks Based On Cash Flows.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com